Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical proucts coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.
Transcript
What will you be talking about during your sessions at AMCP 2022?
AMCP is this spring is in Chicago. My company, IPD Analytics, and myself and my partner Leslie Fish are doing 2 different sessions. They're both pipeline sessions. The first pipeline session will be on traditional pharmaceuticals; that's on Thursday. And then on Friday morning, we're giving the pipeline session on specialty pharmaceuticals.
The traditional session will cover some unique twists on legal and FDA issues that sometimes inhibit launch of products for traditional pharmaceuticals. Then we'll go into the generic pipeline—how payers can save money on products becoming multisource in the coming months; the 505(b)(2) pipeline, that's when manufacturers bring products to market using other products—clinical studies will give some 505(b)(2) pipeline a heads up—and then the brand traditional pharmaceutical pipeline, including new novel products coming to market and also sNDA [supplemental new drug application] products, where they're getting new indications and those new indications could add significant spend. So, that's the traditional one.
On the specialty side, we're going to look at what happened in 2021, give the pipeline outlook for 2022, and then also dig in deep on a couple biosimilar products coming to market, most notably Humira [adalimumab]. And there's been some big changes for payers to understand in the last couple of weeks for both the old formulation and the new formulation.
What other presentations are you looking forward to checking out at AMCP 2022?
I go to AMCP for various reasons. I think, especially in the last couple years with COVID-19, you haven't seen your colleagues that you're used to seeing at different meetings, both pharma colleagues and payer colleagues and other folks you look forward to seeing. I like networking with them. We're in our boxes here working at home so we don't get to interact as much. So, I think I go to AMCP for 2 reasons. One to learn from my colleagues and peers, and then also I go to the session to learn.
The sessions that I'm thinking about are digital therapeutics. IPD is digging into that pretty deep, so I like to hear what other people are thinking. I'm not a big Medicaid guy, but there's 2 Medicaid sessions. One is on carve-in and carve-out for the state programs; I'm interested in that. And also, there's a 340B/Medicaid discussion. 340B is important for anybody in pharmaceuticals today. And then lastly, there's a session on value-based contracting. There's usually a session on that, but I don't think anybody's solved that puzzle and I'm always interested in the next piece of the puzzle.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.